Pro-apoptotic effect of Δ2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.
Fiche publication
Date publication
juillet 2017
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOISBRUN Michel, Pr FLAMENT Stéphane, Dr GRILLIER-VUISSOZ Isabelle, Dr KUNTZ Sandra, Pr GRANDEMANGE Stéphanie
Tous les auteurs :
Geoffroy M, Kleinclauss A, Grandemange S, Hupont S, Boisbrun M, Flament S, Grillier-Vuissoz I, Kuntz S
Lien Pubmed
Résumé
40% of triple-negative breast cancer (TNBC) do not express claudin-1, a major constituent of tight junction. Patients with these "claudin-1-low" tumors present a higher relapse incidence. A major challenge in oncology is the development of innovative therapies for such poor prognosis tumors. In this context, we study the anticancer effects of ∆2-TGZ, a compound derived from troglitazone (TGZ), on cell models of these tumors.
Mots clés
Apoptosis, Claudin-1, Triple-negative breast cancer, Troglitazone derivatives
Référence
Breast Cancer Res. Treat.. 2017 Jul;: